Search by Drug Name or NDC
NDC 44087-0022-03 REBIF 22 ug/.5mL Details
REBIF 22 ug/.5mL
REBIF is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by EMD Serono, Inc.. The primary component is INTERFERON BETA-1A.
MedlinePlus Drug Summary
Interferon beta-1a intramuscular injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Interferon beta-1a is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
Related Packages: 44087-0022-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Interferon Beta-1a Intramuscular Injection
Interferon beta-1a subcutaneous injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Interferon beta-1a is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
Related Packages: 44087-0022-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Interferon Beta-1a Subcutaneous Injection
Product Information
| NDC | 44087-0022 |
|---|---|
| Product ID | 44087-0022_348c7db6-5713-4329-83ca-14925b9b1d69 |
| Associated GPIs | 6240306045E520 |
| GCN Sequence Number | 050035 |
| GCN Sequence Number Description | interferon beta-1a/albumin SYRINGE 22MCG/.5ML SUBCUT |
| HIC3 | H0E |
| HIC3 Description | AGENTS TO TREAT MULTIPLE SCLEROSIS |
| GCN | 15914 |
| HICL Sequence Number | 023353 |
| HICL Sequence Number Description | INTERFERON BETA-1A/ALBUMIN HUMAN |
| Brand/Generic | Brand |
| Proprietary Name | REBIF |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | INTERFERON BETA-1A |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 22 |
| Active Ingredient Units | ug/.5mL |
| Substance Name | INTERFERON BETA-1A |
| Labeler Name | EMD Serono, Inc. |
| Pharmaceutical Class | Interferon beta [EPC], Interferon-beta [CS] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA103780 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 44087-0022-03 (44087002203)
| NDC Package Code | 44087-0022-3 |
|---|---|
| Billing NDC | 44087002203 |
| Package | 12 SYRINGE, GLASS in 1 CARTON (44087-0022-3) / .5 mL in 1 SYRINGE, GLASS (44087-0022-9) |
| Marketing Start Date | 2002-03-07 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 1400.93 |
| Pricing Unit | ML |
| Effective Date | 2021-01-15 |
| NDC Description | REBIF 22 MCG/0.5 ML SYRINGE |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2022-01-12 |